Macrogen operates within the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Macrogen with three other
companies in this sector in South Korea:
sales of 28.45 billion Korean Won [US$25.07 million]
Seoulin Bioscience Company Limited
(42.62 billion Korean Won [US$37.55 million]
Medipost Co Ltd
(42.25 billion Korean Won [US$37.22 million]
of which 46%
was Umbilical Cord Blood).
During the year ended December of 2017, sales at
Macrogen were 101.79 billion Korean Won (US$89.68 million).
increase of 11.7%
versus 2016, when the company's sales were 91.11 billion Korean Won.
This was the fifth consecutive year of sales increases at Macrogen
(and since 2012, sales have increased a total of 131%).
Sales of Others saw an increase
that was more than double the company's growth rate: sales were up
152.5% in 2017, from
866.67 million Korean Won to 2.19 billion Korean Won.
Macrogen also saw significant increases in sales in
Ces (up 29.0% to 32.46 billion Korean Won)